Structure-based screening identified three TLR4-targeting small molecules. NSF-951 showed strong agonist and adjuvant activity, while NSF418 and NSF-501 acted as antagonists. NSF-951 is a promising, cost-effective alternative to MPLA for vaccine development
- Mohammad Kadivella
- Vivek P. Varma
- Syed M. Faisal